
抗癌新靶标之ADAM9—ADC、单抗、小分子抑制剂研究 - 知乎
ADAM9(A distegrinin and a metalloprotease 9)是一种膜锚定蛋白,主要通过用于粘附的分解蛋白结构域和用于脱落多种细胞表面蛋白的 金属蛋白结构域 参与多种生理功能。 近年越来越多的证据表明ADAM9在肿瘤中发挥着重要作用。 在多种癌症中发现了ADAM9的过量表达,并与肿瘤侵袭性和不良预后相关。 此外,通过 蛋白水解 或非蛋白水解途径,ADAM9促进了肿瘤的进展、治疗的抗性和癌症的转移。 本文描述了目前对ADAM9在生物学功能、病理生理学疾病和各种癌症中 …
An Overview of ADAM9: Structure, Activation, and Regulation in …
ADAM9-S is a secreted protein, lacking the transmembrane and cytoplasmic domains via excising exon 12 from the ADAM9 mRNA, and contains 8 unique amino acids (LSLKFHAPF) not present in ADAM9-L. ADAM9-S promotes cancer cell migration and invasion via its metalloprotease activity and is also able to bind directly to α6β4 and α2β1 integrins on ...
A pan-cancer study of ADAM9’s immunological function and
2024年11月6日 · Immunohistochemistry (IHC) staining from 90 pathologically verified samples proved the positive correlation between ADAM9 and tumor stages and proved the higher expression of ADAM9 correlated...
An Overview of ADAM9: Structure, Activation, and Regulation in …
2020年10月21日 · ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins.
ADAM9在实体肿瘤生物学中的相关研究进展 - 汉斯出版社
肿瘤组织中adam9表达明显高于正常胃组织,体外应用抗adam9抗体抑制胃癌细胞的生长,提示adam9通过信号分子的脱落或与粘附分子的相互作用在细胞增殖中发挥作用,在表达最高水平adam9的gc细胞中,敲除adam9减弱了细胞增殖,这与细胞周期阻滞在g0/g1期相一致 [33]。
An Overview of ADAM9: Structure, Activation, and Regulation in …
2020年10月21日 · ADAM9-S is a secreted protein, lacking the transmembrane and cytoplasmic domains via excising exon 12 from the ADAM9 mRNA, and contains 8 unique amino acids (LSLKFHAPF) not present in ADAM9-L. ADAM9-S promotes cancer cell migration and invasion via its metalloprotease activity and is also able to bind directly to α6β4 and α2β1 integrins on ...
被AbbVie放弃的ADAM9 ADC,抗癌效力究竟几何? - 百家号
2024年7月25日 · ADAM9-S是一种分泌蛋白,通过切除ADAM9 mRNA中的外显子12而缺乏跨膜和胞质结构域,并含有8个ADAM9-L中不存在的独特氨基酸 (LSLKFHAPF)。 ADAM9作为蛋白酶,可在在细胞表面剪切许多底物,包括细胞粘附分子和生长因子,这对正常细胞黏附和迁移至关重要。 此外,ADAM9还参与细胞的迁移和增殖,促进细胞侵袭和转移,并与细胞融合和细胞凋亡等过程相关。 这些功能的紊乱与多种疾病的发展密切相关。 ADAM9广泛表达于人体组织中,包括肺、 …
ADAM9 Gene - GeneCards | ADAM9 Protein | ADAM9 Antibody
2024年12月24日 · ADAM9 (ADAM Metallopeptidase Domain 9) is a Protein Coding gene. Diseases associated with ADAM9 include Cone-Rod Dystrophy 9 and Cone-Rod Dystrophy 2. Among its related pathways are Extracellular matrix organization and Collagen chain trimerization. Gene Ontology (GO) annotations related to this gene include SH3 domain binding and …
被AbbVie放弃的ADAM9 ADC,抗癌效力究竟几何? - 专注肿瘤免疫
2024年7月30日 · ADAM9-S是一种分泌蛋白,通过切除ADAM9 mRNA中的外显子12而缺乏跨膜和胞质结构域,并含有8个ADAM9-L中不存在的独特氨基酸 (LSLKFHAPF)。 ADAM9作为蛋白酶,可在在细胞表面剪切许多底物,包括细胞粘附分子和生长因子,这对正常细胞黏附和迁移至关重要。 此外,ADAM9还参与细胞的迁移和增殖,促进细胞侵袭和转移,并与细胞融合和细胞凋亡等过程相关。 这些功能的紊乱与多种疾病的发展密切相关。 ADAM9广泛表达于人体组织中,包括肺、 …
Structure, regulatory factors and cancer-related physiological …
In studies on breast cancer, ADAM9-S was found to positively promote tumor cell migration, in contrast to ADAM9-L, which greatly diminished this effect or inhibited tumor migration. Considered in this context, the two ADAM9 splice variants are mutually bound to each other in the organism and act as magical stabilizers[ 40 ].
抗癌新靶标ADAM9有何过人之处 - 知乎 - 知乎专栏
2023年2月2日 · IMGC936 是由ImmunoGen与Macrogenics合作开发的首款靶向ADAM9的新型 ADC,用于治疗非小细胞肺癌,胃癌,胰腺癌,三阴性乳腺癌和结直肠癌等实体瘤。 在2021年的AACR上公布的数据显示出IMGC936在多种实体瘤中良好的活性,目前处于I期临床阶段。 IMGC936是由高亲和力的人源化单克隆抗体、美登木素生物碱微管抑制剂载荷和稳定的三肽接头组成的一款创新ADC药物,DAR值为2。 此外,YTE 突变 (M252Y/S254T/T256E) 被引入抗 …
Deciphering the oncogenic potential of ADAM9 in hepatocellular ...
2024年11月2日 · Our results demonstrate that high ADAM9 expression is associated with poor prognosis and increased immune infiltration in HCC patients. Furthermore, ADAM9 knockdown significantly inhibited...
ADAM9 promotes type I interferon-mediated innate immunity
2024年5月16日 · ADAM9 is implicated in a range of human diseases, including inflammatory diseases; however, its role in viral infection is unknown. Here, we demonstrate that mice lacking ADAM9 are more...
Structure, regulatory factors and cancer-related physiological effects ...
The ADAMs family belongs to the transmembrane protein superfamily of zinc-dependent metalloproteases, which consists of multiple domains. These domains have independent but complementary functions that enable them to participate in multiple biological processes. Among them, ADAM9 can not only partic …
Full article: Structure, regulatory factors and cancer-related ...
2020年9月12日 · In studies on breast cancer, ADAM9-S was found to positively promote tumor cell migration, in contrast to ADAM9-L, which greatly diminished this effect or inhibited tumor migration. Considered in this context, the two ADAM9 splice variants are mutually bound to each other in the organism and act as magical stabilizers[ Citation 40 ].
抗癌新靶标之ADAM9—ADC、单抗、小分子抑制剂研究医药新闻-B…
ADAM9(A distegrinin and a metalloprotease 9)是一种膜锚定蛋白,主要通过用于粘附的分解蛋白结构域和用于脱落多种细胞表面蛋白的金属蛋白结构域参与多种生理功能。 近年越来越多的证据表明ADAM9在肿瘤中发挥着重要作用。 在多种癌症中发现了ADAM9的过量表达,并与肿瘤侵袭性和不良预后相关。 此外,通过蛋白水解或非蛋白水解途径,ADAM9促进了肿瘤的进展、治疗的抗性和癌症的转移。 本文描述了目前对ADAM9在生物学功能、病理生理学疾病和各种癌症中的 …
抗癌新靶标ADAM9有何过人之处 - 新浪财经
2023年1月31日 · IMGC936是由ImmunoGen与Macrogenics合作开发的首款靶向ADAM9的新型 ADC,用于治疗非小细胞肺癌,胃癌,胰腺癌,三阴性乳腺癌和结直肠癌等实体瘤。 在2021年的AACR上公布的数据显示出IMGC936在多种实体瘤中良好的活性,目前处于I期临床阶段。 IMGC936是由高亲和力的人源化单克隆抗体、美登木素生物碱微管抑制剂载荷和稳定的三肽接头组成的一款创新ADC药物,DAR值为2。 此外,YTE 突变 (M252Y/S254T/T256E) 被引入抗 …
Inhibition of ADAM9 promotes the selective degradation of KRAS …
2024年1月24日 · Suppression of ADAM9 by a small-molecule inhibitor restricts disease progression in spontaneous models, and combination with gemcitabine elicits dramatic regression of patient-derived tumors.
An Overview of ADAM9: Structure, Activation, and
2020年10月21日 · ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin...
ADAM9 functions as a transcriptional regulator to drive angiogenesis …
2021年9月7日 · Hypoxia and angiogenesis play key roles in the pathogenesis of esophageal squamous cell carcinoma (ESCC), but regulators linking these two pathways to drive tumor progression remain elusive. Here we provide evidence …
- 某些结果已被删除